用重组人白细胞介素-13治疗葡萄膜炎。
Treatment of uveitis with recombinant human interleukin-13.
作者信息
Roberge F G, de Smet M D, Benichou J, Kriete M F, Raber J, Hakimi J
机构信息
National Institutes of Health, National Eye Institute, Bethesda, Maryland, USA.
出版信息
Br J Ophthalmol. 1998 Oct;82(10):1195-8. doi: 10.1136/bjo.82.10.1195.
AIM
To evaluate the anti-inflammatory cytokine interleukin-13 (IL-13) for the treatment of uveitis.
METHODS
Uveitis was induced in monkeys by immunisation with human retinal S-antigen. Starting at the onset of disease, the animals were treated with IL-13 at 25 micrograms/kg, or vehicle control, injected subcutaneously once a day for 28 days. Intraocular inflammation was scored by indirect ophthalmoscopy for a period of 56 days. Circulating leucocyte levels were monitored.
RESULTS
Uveitis started unilaterally in all but one animal. IL-13 inhibited inflammation both in the eyes in which the disease was present when the treatment was initiated (p = 0.0001), and in the contralateral initially negative eyes (p = 0.0001). After cessation of therapy, there was a progressive increase of inflammation in the IL-13 treated group. However, the beneficial effect of IL-13 extended into the 4 week follow up period. IL-13 produced an increase in circulating polymorphonuclear neutrophils and a decrease in lymphocytes.
CONCLUSION
Administration of IL-13 appears to be a promising modality of treatment for severe uveitis.
目的
评估抗炎细胞因子白细胞介素 - 13（IL - 13）治疗葡萄膜炎的效果。
方法
通过用人视网膜S抗原免疫诱导猴子发生葡萄膜炎。从疾病发作开始，动物分别接受25微克/千克的IL - 13治疗或赋形剂对照，每天皮下注射一次，持续28天。通过间接检眼镜检查对眼内炎症进行评分，为期56天。监测循环白细胞水平。
结果
除一只动物外，所有动物的葡萄膜炎均单侧发病。IL - 13在治疗开始时已发病的眼睛中抑制炎症（p = 0.0001），在对侧最初未发病的眼睛中也抑制炎症（p = 0.0001）。治疗停止后，IL - 13治疗组的炎症逐渐加重。然而，IL - 13的有益作用持续到4周的随访期。IL - 13使循环中的多形核中性粒细胞增加，淋巴细胞减少。
结论
给予IL - 13似乎是治疗严重葡萄膜炎的一种有前景的方法。
Zotero 插件